Invesco
XERS icon

Invesco’s Xeris Biopharma Holdings XERS Stock Holding History

Invesco’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$870K Buy
109,875
+6,581
+6% +$42K ﹤0.01% 2992
2026
Q1 		$599K Sell
103,294
-8,836
-8% -$58.6K ﹤0.01% 3087
2025
Q4 		$880K Sell
112,130
-470,978
-81% -$3.71M ﹤0.01% 2967
2025
Q3 		$4.75M Buy
583,108
+496,914
+577% +$3.3M ﹤0.01% 2255
2025
Q2 		$403K Sell
86,194
-940,644
-92% -$4.31M ﹤0.01% 3261
2025
Q1 		$5.64M Buy
1,026,838
+957,822
+1,388% +$3.87M ﹤0.01% 2090
2024
Q4 		$234K Buy
69,016
+1,350
+2% +$4.34K ﹤0.01% 3487
2024
Q3 		$193K Buy
67,666
+1,137
+2% +$2.92K ﹤0.01% 3526
2024
Q2 		$150K Buy
66,529
+2,727
+4% +$5.5K ﹤0.01% 3699
2024
Q1 		$141K Buy
63,802
+625
+1% +$1.62K ﹤0.01% 3708
2023
Q4 		$148K Sell
63,177
-256,471
-80% -$473K ﹤0.01% 3620
2023
Q3 		$595K Sell
319,648
-1,784,974
-85% -$4.09M ﹤0.01% 3119
2023
Q2 		$5.51M Buy
2,104,622
+2,285
+0.1% +$5.82K ﹤0.01% 2183
2023
Q1 		$3.43M Buy
2,102,337
+2,276
+0.1% +$2.85K ﹤0.01% 2402
2022
Q4 		$2.79M Sell
2,100,061
-6,994
-0.3% -$9.87K ﹤0.01% 2510
2022
Q3 		$3.29M Buy
2,107,055
+6,849
+0.3% +$11.3K ﹤0.01% 2426
2022
Q2 		$3.23M Buy
2,100,206
+62,816
+3% +$133K ﹤0.01% 2495
2022
Q1 		$5.22M Buy
2,037,390
+1,264
+0.1% +$3.09K ﹤0.01% 2354
2021
Q4 		$5.97M Sell
2,036,126
-688
-0% -$1.49K ﹤0.01% 2310
2021
Q3 		$4.99M Sell
2,036,814
-488
-0% -$1.42K ﹤0.01% 2386
2021
Q2 		$8.29M Sell
2,037,302
-7,718
-0.4% -$29.5K ﹤0.01% 2171
2021
Q1 		$9.22M Buy
2,045,020
+1,969
+0.1% +$10.6K ﹤0.01% 1997
2020
Q4 		$10.1M Buy
2,043,051
+41,063
+2% +$205K ﹤0.01% 1809
2020
Q3 		$11.9M Buy
2,001,988
+105
+0% +$420 ﹤0.01% 1572
2020
Q2 		$5.33M Buy
2,001,883
+1,000,000
+100% +$3.48M ﹤0.01% 1959
2020
Q1 		$1.95M Buy
1,001,883
+1,883
+0.2% +$8.1K ﹤0.01% 2409
2019
Q4 		$7.05M Hold
1,000,000
– – ﹤0.01% 1953
2019
Q3 		$9.83M Hold
1,000,000
– – ﹤0.01% 1749
2019
Q2 		$11.4M Buy
+1,000,000
New +$10.5M ﹤0.01% 1693

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco's XERS Position: Q2 2026 in Review

Invesco increased its Xeris Biopharma Holdings (XERS) stake by 6.4% in Q2 2026, buying an estimated $42K and bringing the position to 109,875 shares worth $870K. The position accounts for ﹤0.01% of the portfolio, ranked #2992.

Invesco first reported a position in XERS in Q2 2019 and has held it in 29 quarters since. The position peaked at $11.9M in Q3 2020. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Invesco held 109,875 shares of Xeris Biopharma Holdings worth $870K as of Q2 2026.
  • Invesco bought 6,581 Xeris Biopharma Holdings shares in Q2 2026, an estimated $42K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2992 holding.
  • Invesco first reported a position in Xeris Biopharma Holdings in Q2 2019 and has held it in 29 quarters since.
  • Invesco's Xeris Biopharma Holdings position peaked at $11.9M in Q3 2020.
  • 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.